Inventor · disambiguated record
Tom Miller
Also filed as: MILLER TOM
8 granted patents·4 pending applications·52 citations·filing 2014–2020
86Inventor score
Top patents by PatentIndex Score
12 records- 0193US11040957B2Heteroaromatic compounds useful for the treatment of proliferative diseasesSYROS PHARMACEUTICALS INC·Filed 2018·Granted Jun 22, 2021·7 cites·21 claims
- 0292US10059690B2Inhibitors of cyclin-dependent kinase 7 (CDK7)SYROS PHARMACEUTICALS INC·Filed 2017·Granted Aug 28, 2018·9 cites·19 claims
- 0391US10047070B2Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)DANA FARBER CANCER INST INC·Filed 2014·Granted Aug 14, 2018·17 cites·19 claims
- 0486US10308648B2Inhibitors of cyclin-dependent kinase 7 (CDK7)SYROS PHARMACEUTICALS INC·Filed 2015·Granted Jun 4, 2019·6 cites·20 claims
- 0585US10106526B2Inhibitors of cyclin-dependent kinase 7 (CDK7)SYROS PHARMACEUTICALS INC·Filed 2015·Granted Oct 23, 2018·5 cites·19 claims
- 0684US10906889B2Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)DANA FARBER CANCER INST INC·Filed 2018·Granted Feb 2, 2021·4 cites·32 claims
- 0784US10519135B2Inhibitors of cyclin-dependent kinase 7 (CDK7)SYROS PHARMACEUTICALS INC·Filed 2018·Granted Dec 31, 2019·3 cites·18 claims
- 0879US10865206B2Inhibitors of cyclin-dependent kinase 7 (CDK7)SYROS PHARMACEUTICALS INC·Filed 2019·Granted Dec 15, 2020·1 cites·25 claims
- 0965US2021061803A1Inhibitors of cyclin-dependent kinase 7 (cdk7)SYROS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1060US2016264551A1Heteroaromatic compounds useful for the treatment of prolferative diseasesSYROS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 1153US2016264552A1Heteromaromatic compounds useful for the treatment of prolferative diseasesSYROS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 1251US2019292167A1Heteroaromatic compounds useful for the treatment of proliferative diseasesSYROS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Tom Miller files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →